AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29848993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 26965540 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables present at the time of MI (including EF at presentation, length of stay, prior MI, lateral wall motion abnormality, peak troponin)
Number of subjects: 231
Study 26965540 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables present at the time of MI (including EF at presentation, peak troponin, prior MI, presentation with ventricular fibrillation or cardiac arrest)
Number of subjects: 231
Study 26965540 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 231
Study 24242334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal progesterone implant between days 3 and 7 following fixed-time artificial insemination (FTAI)
Number of subjects: 2
Study 24242334 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2
Study 22750958 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified CIMT
Number of subjects: 28
Study 22750958 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 28
Study 19157346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron plus subhypnotic propofol infusion
Number of subjects: 140
Study 19157346 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron alone
Number of subjects: 140
Study 17978121 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial training workshop on shoulder dystocia management (40 minutes)
Number of subjects: 122
Study 17978121 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional training for those who could not deliver after initial training
Number of subjects: 122
Study 15034285 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose omeprazole (L-OMP: 10 mg, q.d.)
Number of subjects: 100
Study 15034285 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose ranitidine (S-H2RA: 150 mg, b.i.d.)
Number of subjects: 100
Study 11479461 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoflux (1, 4, 8, or 16 mg/kg as a bolus followed by 1, 4, 8, or 16 mg/kg per hour infusion)
Number of subjects: 277
Study 11479461 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 277
Study 11479461 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoflux (8 or 16 mg/kg)
Number of subjects: 277
Study 9517745 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior mesenteric artery clamp
Number of subjects: 40
Study 9517745 — intervention group
Group type: COMPARATOR
Intervention: Nonclamp
Number of subjects: 40
Study 11271221 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmun Neoral (NOF)
Number of subjects: 0
Study 11271221 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun (SIM)
Number of subjects: 0
Study 3126339 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (70 mg with an initial bolus of 10 mg)
Number of subjects: 125
Study 3126339 — intervention group
Group type: COMPARATOR
Intervention: Urokinase (3 million U with an initial bolus of 1.5 million U)
Number of subjects: 125
Study 3126339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rt-PA and Urokinase
Number of subjects: 125
Study 29072931 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina treatment
Number of subjects: 92
Study 26962636 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiofrequency (RF) device combining RF heat, suction coupled vacuum, and oscillating electrical pulses
Number of subjects: 20
Study 26962636 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiofrequency (RF) device
Number of subjects: 20
Study 24968970 — intervention group
Group type: EXPERIMENTAL
Intervention: GTx‐758 1000 mg/d
Number of subjects: 159
Study 24968970 — intervention group
Group type: EXPERIMENTAL
Intervention: GTx‐758 2000 mg/d
Number of subjects: 159
Study 24968970 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 159
Study 24968970 — intervention group
Group type: EXPERIMENTAL
Intervention: GTx‐758
Number of subjects: 159
Study 24002501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg per day)
Number of subjects: 330
Study 24002501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 20391062 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based HIV/STI risk-reduction intervention (CHSR)
Number of subjects: 80
Study 20391062 — intervention group
Group type: COMPARATOR
Intervention: Attentional control wellness promotion (WP)
Number of subjects: 80
Study 18189207 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support variables for women
Number of subjects: 435
Study 18189207 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support variables for men
Number of subjects: 435
Study 18189207 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing social support
Number of subjects: 435
Study 18189207 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐using sexual partners for men
Number of subjects: 435
Study 16324861 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine 0.1 mg kg(‐1) with ketamine 0.15 mg kg(‐1) (group KM)
Number of subjects: 69
Study 12067327 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg/day)
Number of subjects: 17
Study 10340240 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Fatigue Syndrome (CFS)
Number of subjects: 65
Study 10340240 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD)
Number of subjects: 65
Study 10340240 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 65
Study 8572782 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration
Number of subjects: 50
Study 8572782 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrafiltration
Number of subjects: 50
Study 8572782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Modified and Conventional ultrafiltration)
Number of subjects: 50
Study 1936509 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 0
Study 1936509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6790966 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-Dihydergot 2500
Number of subjects: 350
Study 6790966 — intervention group
Group type: COMPARATOR
Intervention: Conventional low dose heparin regimen
Number of subjects: 350
Study 30098049 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic exposure (defined by four methods for each of four anticholinergic scales: Anticholinergic Drug Scale, Anticholinergic Cognitive Burden, Anticholinergic Risk Scale, the Durán list)
Number of subjects: 1396
Study 30098049 — intervention group
Group type: COMPARATOR
Intervention: Non-anticholinergic agent users
Number of subjects: 1396
Study 27428644 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback (VI) group
Number of subjects: 59
Study 27428644 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL) group
Number of subjects: 59
Study 25639827 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Number of subjects: 58
Study 25639827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord milking
Number of subjects: 58
Study 25022109 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Zusanli (ST 36) and Neiguan (PC 6) with additional points based on syndrome differentiation, stimulated with disperse-dense wave at 2 Hz/100 Hz, once a day for 4 sessions (5 days each session)
Number of subjects: 70
Study 25022109 — intervention group
Group type: COMPARATOR
Intervention: Domperidone, 10 mg orally, three times a day for 4 sessions (5 days each session)
Number of subjects: 70
Study 23063071 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab (MetMAb) plus erlotinib (150 mg oral daily)
Number of subjects: 490
Study 23063071 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone (150 mg oral daily)
Number of subjects: 490
Study 19039022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cpn10 (5 mg or 10 mg weekly for 12 weeks)
Number of subjects: 50
Study 19039022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17329479 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of memantine
Number of subjects: 38
Study 17329479 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of memantine
Number of subjects: 38
Study 17329479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 15249354 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose
Number of subjects: 195
Study 15249354 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability function based on GLUMEAN and GLUSD
Number of subjects: 195
Study 11114445 — intervention group
Group type: EXPERIMENTAL
Intervention: Braced condition
Number of subjects: 4
Study 11114445 — intervention group
Group type: COMPARATOR
Intervention: Non-braced condition
Number of subjects: 4
Study 10450451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) administration of one-fifth dose of purified Vero-cell rabies vaccine (PVRV) with routine DTP-IPV vaccines (2, 3, 4 months)
Number of subjects: 240
Study 10450451 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) administration of 2 doses of PVRV (2, 4 months) with routine DTP-IPV vaccines (2, 3, 4 months)
Number of subjects: 240
Study 7846538 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent ifosfamide
Number of subjects: 0
Study 7846538 — intervention group
Group type: COMPARATOR
Intervention: Standard combination chemotherapy (cyclophosphamide/doxorubicin/vincristine)
Number of subjects: 0
Study 7846538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide combined with carboplatin and etoposide
Number of subjects: 0
Study 2129649 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol 2.5 g b.d.
Number of subjects: 40
Study 2129649 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol 5 g b.d.
Number of subjects: 40
Study 2129649 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol 7.5 g b.d.
Number of subjects: 40
Study 2129649 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.d.
Number of subjects: 40
Study 6171687 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin (300 mg single dose)
Number of subjects: 16
Study 6171687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31263524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP) training, 8 sessions
Number of subjects: 70
Study 31263524 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 27997327 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation and therapeutic exposure (BA-TE)
Number of subjects: 45
Study 23710900 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral condensation
Number of subjects: 18
Study 23710900 — intervention group
Group type: COMPARATOR
Intervention: Bone drilling
Number of subjects: 18
Study 23710900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 18
Study 22289389 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave energy device treatment
Number of subjects: 120
Study 22289389 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 120
Study 20305369 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training program (aerobic, muscle strength, balance)
Number of subjects: 96
Study 20305369 — intervention group
Group type: COMPARATOR
Intervention: Nutritional intervention program (individually targeted advice and group sessions)
Number of subjects: 96
Study 20305369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physical training and nutritional intervention
Number of subjects: 96
Study 20305369 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 18298870 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml semi-skimmed milk (1200 mg calcium)
Number of subjects: 30
Study 18298870 — intervention group
Group type: COMPARATOR
Intervention: No milk supplement
Number of subjects: 30
Study 16117978 — intervention group
Group type: EXPERIMENTAL
Intervention: FF‐muG 130 mg with food
Number of subjects: 146
Study 16117978 — intervention group
Group type: EXPERIMENTAL
Intervention: FF‐muG 130 mg without food
Number of subjects: 146
Study 16117978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 14685054 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg once daily
Number of subjects: 467
Study 14685054 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 600 mg once daily
Number of subjects: 467
Study 14685054 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir 1250 mg twice a day
Number of subjects: 467
Study 10863994 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (LS; sodium chloride intake <5 g per day)
Number of subjects: 10
Study 10863994 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-salt diet (NS; normal food ad libitum)
Number of subjects: 10
Study 10863994 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (HS; normal food plus NaCl 100 mg/kg per day)
Number of subjects: 10
Study 10863994 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute oral water load of 1500 ml
Number of subjects: 10
Study 8667868 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 1599
Study 8667868 — intervention group
Group type: COMPARATOR
Intervention: Non-surgery (control)
Number of subjects: 1599
Study 1625504 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m. for four weeks
Number of subjects: 24
Study 1625504 — intervention group
Group type: COMPARATOR
Intervention: Placebo for four weeks
Number of subjects: 24
Study 1625504 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole-treated patients re-examined 10 days after drug withdrawal
Number of subjects: 24
Study 1625504 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole-treated patients re-examined 15 days after drug withdrawal
Number of subjects: 24
Study 6613908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish consumption (100 g or more at least twice a week for 3 months)
Number of subjects: 118
Study 6613908 — intervention group
Group type: COMPARATOR
Intervention: Little or no fatty fish (for another 3 months)
Number of subjects: 118
Study 3960476 — intervention group
Group type: EXPERIMENTAL
Intervention: The Meditec OPL3 mode‐locked Nd:YAG laser
Number of subjects: 0
Study 3960476 — intervention group
Group type: EXPERIMENTAL
Intervention: The LASAG Microruptor 2 Q‐switched Nd:YAG laser
Number of subjects: 0
Study 3960476 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Indomethacin and topical steroid treatment
Number of subjects: 0
Study 3960476 — intervention group
Group type: COMPARATOR
Intervention: Placebo with topical steroids
Number of subjects: 0
Study 31663173 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-follicular phase
Number of subjects: 30
Study 31663173 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-luteal phase
Number of subjects: 30
Study 31663173 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive-pill phase
Number of subjects: 30
Study 31663173 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-pill phase
Number of subjects: 30
Study 31663173 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-follicular phase (non-oral contraceptive users)
Number of subjects: 30
Study 31663173 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-luteal phase (non-oral contraceptive users)
Number of subjects: 30
Study 29912858 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (∼280 mg)
Number of subjects: 9
Study 29912858 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 9
Study 27343175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole treatment for 2 months
Number of subjects: 40
Study 27343175 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal coronary arteries)
Number of subjects: 40
Study 27343175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI) measurements
Number of subjects: 40
Study 27343175 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Doppler parameters
Number of subjects: 40
Study 24365194 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C infusion (3-g infusion within 6 hours before PCI)
Number of subjects: 532
Study 24365194 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 532
Study 23260537 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask
Number of subjects: 45
Study 23260537 — intervention group
Group type: COMPARATOR
Intervention: Tongue appliance
Number of subjects: 45
Study 20889601 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA plus MTX
Number of subjects: 799
Study 20889601 — intervention group
Group type: COMPARATOR
Intervention: ADA
Number of subjects: 799
Study 20889601 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 799
Study 19192867 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary reinforcement accrued with consecutive instances of abstinence
Number of subjects: 0
Study 19192867 — intervention group
Group type: COMPARATOR
Intervention: Money deducted for failure to abstain
Number of subjects: 0
Study 15668427 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg testosterone enanthate plus daily oral placebo pill (T group, n = 20)
Number of subjects: 60
Study 15668427 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg testosterone enanthate plus 1 mg daily of anastrozole (AT group, n = 19)
Number of subjects: 60
Study 15668427 — intervention group
Group type: COMPARATOR
Intervention: Saline injection and placebo pill (placebo group, n = 21)
Number of subjects: 60
Study 14566150 — intervention group
Group type: EXPERIMENTAL
Intervention: Square plate (30 x 30 mm) under the left lateral plantar eminence
Number of subjects: 8
Study 14566150 — intervention group
Group type: COMPARATOR
Intervention: Square plate (3 mm or 6 mm thickness) under the left medial plantar eminence
Number of subjects: 8
Study 14566150 — intervention group
Group type: COMPARATOR
Intervention: Square plate (3 mm or 6 mm thickness) under the left forefoot sole
Number of subjects: 8
Study 14566150 — intervention group
Group type: COMPARATOR
Intervention: Rectangular plate (120 x 30 mm) under the left metatarsal heads (3 mm or 6 mm thickness)
Number of subjects: 8
Study 10950767 — intervention group
Group type: EXPERIMENTAL
Intervention: Rtv/Sqv
Number of subjects: 318
Study 10950767 — intervention group
Group type: EXPERIMENTAL
Intervention: Rtv
Number of subjects: 318
Study 10950767 — intervention group
Group type: EXPERIMENTAL
Intervention: Idr
Number of subjects: 318
Study 10950767 — intervention group
Group type: COMPARATOR
Intervention: All arms
Number of subjects: 318
Study 9004341 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad eligibility criteria for clozapine
Number of subjects: 505
Study 9004341 — intervention group
Group type: EXPERIMENTAL
Intervention: Stringent eligibility criteria for clozapine
Number of subjects: 505
Study 1477491 — intervention group
Group type: EXPERIMENTAL
Intervention: zuclopenthixol dihydrochloride tablets (10 mg)
Number of subjects: 52
Study 1477491 — intervention group
Group type: COMPARATOR
Intervention: placebo tablets
Number of subjects: 52
Study 30704571 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery combined with optimal medical therapy (OMT)
Number of subjects: 4953
Study 30704571 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG + OMT
Number of subjects: 4953
Study 30704571 — intervention group
Group type: COMPARATOR
Intervention: CKD (mild and moderate to severe)
Number of subjects: 4953
Study 29769828 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 min RW
Number of subjects: 13
Study 29769828 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 min RW
Number of subjects: 13
Study 29769828 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study 27614374 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie-guided single lung intubation
Number of subjects: 45
Study 24465443 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg daily with lopinavir/ritonavir
Number of subjects: 33
Study 24465443 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg three times per week with lopinavir/ritonavir
Number of subjects: 33
Study 24465443 — intervention group
Group type: COMPARATOR
Intervention: Rifabutin 300 mg alone
Number of subjects: 33
Study 24465443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing regimens of rifabutin
Number of subjects: 33
Study 23131372 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure intervention on Shenmen (He7), He Gu (Li4), and Sanyingjao (sp6) points for 4 weeks alongside routine care
Number of subjects: 48
Study 23131372 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 48
Study 20573975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypergravity condition
Number of subjects: 20
Study 20573975 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic phases under hypergravity
Number of subjects: 20
Study 20573975 — intervention group
Group type: COMPARATOR
Intervention: Control test with increased object mass
Number of subjects: 20
Study 20573975 — intervention group
Group type: COMPARATOR
Intervention: Control test with change in movement kinematics
Number of subjects: 20
Study 17696277 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg prednisolone daily (n = 34)
Number of subjects: 67
Study 17696277 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone (n = 33)
Number of subjects: 67
Study 17696277 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treated for at least 4 years
Number of subjects: 67
Study 16181540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract injection (GB)
Number of subjects: 60
Study 16181540 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 60
Study 12057714 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene, 60 mg/d for 3 months
Number of subjects: 40
Study 12057714 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 40
Study 12057714 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 40